ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

ClinicalTrials.gov ID: NCT05001282

Public ClinicalTrials.gov record NCT05001282. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors

Study identification

NCT ID
NCT05001282
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Elucida Oncology
Industry
Enrollment
79 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 12, 2021
Primary completion
Jun 6, 2024
Completion
Jun 6, 2024
Last update posted
Aug 6, 2024

2021 – 2024

United States locations

U.S. sites
18
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Mayo Clinic - Phoenix, AZ Phoenix Arizona 85054
Providence Medical Foundation Fullerton California 92835
Mayo Clinic - Jacksonville, FL Jacksonville Florida 32224
D&H Cancer Research Center Margate Florida 33063
Sarah Cannon Research Institute at Florida Cancer Specialists Orlando Florida 32827
Hope and Healing Cancer Services Hinsdale Illinois 60521
OSF Saint Francis Medical Center Peoria Illinois 61606
Mayo Clinic - Rochester, MN Rochester Minnesota 55905
Memorial Sloan Kettering Cancer Center New York New York 10065
Duke University Medical Center - Duke Cancer Institute Durham North Carolina 27719
Cleveland Clinic Cleveland Ohio 44195
Thomas Jefferson University, Sidney Kimmel Cancer Center Philadelphia Pennsylvania 19107
Women & Infants Hospital of Rhode Island Providence Rhode Island 02905
Avera Cancer Institute Sioux Falls South Dakota 57105
Sarah Cannon Research Institute at Tennessee Oncology Nashville Tennessee 37203
Mary Crowley Cancer Research Dallas Texas 75230
New Experimental Therapeutics of San Antonio (NEXT Oncology) San Antonio Texas 78229
Fred Hutchinson Cancer Center Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05001282, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 6, 2024 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05001282 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →